These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 10526627

  • 1. Comparison of different tracers in the follow up of differentiated thyroid carcinoma.
    Lind P, Gallowitsch HJ, Mikosch P, Kresnik E, Gomez I, Kumnig G, Matschnig S, Unterweger O, Dinges HP, Starlinger M.
    Acta Med Austriaca; 1999; 26(4):115-7. PubMed ID: 10526627
    [Abstract] [Full Text] [Related]

  • 2. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P, Gallowitsch HJ.
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [Abstract] [Full Text] [Related]

  • 3. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P, Kohlfürst S.
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [Abstract] [Full Text] [Related]

  • 4. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S, Hadjieva T, Doldurova M, Stefanova S, Dudov A.
    J BUON; 2006 Jul; 11(4):511-8. PubMed ID: 17309186
    [Abstract] [Full Text] [Related]

  • 5. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ, Mikosch P, Kresnik E, Unterweger O, Gomez I, Lind P.
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [Abstract] [Full Text] [Related]

  • 6. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, Yoshinaga K, Katoh C, Kuge Y, Tamaki N.
    J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
    [Abstract] [Full Text] [Related]

  • 7. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
    Kohlfuerst S, Igerc I, Gallowitsch HJ, Gomez I, Kresnik E, Matschnig S, Lind P.
    Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
    [Abstract] [Full Text] [Related]

  • 8. Detecting metastatic neck lymph nodes in papillary thyroid carcinoma by 18F-2-deoxyglucose positron emission tomography and Tc-99m tetrofosmin single photon emission computed tomography.
    Wu YJ, Wu HS, Yen RF, Shen YY, Kao CH.
    Anticancer Res; 2003 Nov; 23(3C):2973-6. PubMed ID: 12926147
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 18F-FDG-PET in the follow-up of thyroid cancer.
    Lind P, Kresnik E, Kumnig G, Gallowitsch HJ, Igerc I, Matschnig S, Gomez I.
    Acta Med Austriaca; 2003 Nov; 30(1):17-21. PubMed ID: 12558561
    [Abstract] [Full Text] [Related]

  • 11. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
    Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K, Hahn K.
    J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
    [Abstract] [Full Text] [Related]

  • 14. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
    Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W.
    J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Positron emission tomography for the detection of metastases of differentiated thyroid carcinoma.
    Lips P, Comans EF, Hoekstra OS, van der Poest Clement E, van Mourik JC, Teule GJ.
    Neth J Med; 2000 Oct; 57(4):150-6. PubMed ID: 11006491
    [Abstract] [Full Text] [Related]

  • 17. [Value of F-18 fluorodeoxyglucose positron emission tomography in thyroid carcinoma].
    Kumnig G.
    Wien Med Wochenschr; 2002 Oct; 152(11-12):280-5. PubMed ID: 12138656
    [Abstract] [Full Text] [Related]

  • 18. Radio-guided surgery for non-131I-avid thyroid cancer.
    Rubello D, Pelizzo MR, Casara D, Piotto A, Toniato A, Fig L, Gross M.
    Thyroid; 2006 Nov; 16(11):1105-11. PubMed ID: 17123337
    [Abstract] [Full Text] [Related]

  • 19. Tc-99m-tetrofosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma--preliminary results.
    Gallowitsch HJ, Kresnik E, Mikosch P, Pipam W, Gomez I, Lind P.
    Nuklearmedizin; 1996 Dec; 35(6):230-5. PubMed ID: 8976503
    [Abstract] [Full Text] [Related]

  • 20. 131I whole body scintigraphy in thyroid cancer patients.
    Lind P.
    Q J Nucl Med; 1999 Sep; 43(3):188-94. PubMed ID: 10568134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.